Cod­ed cal­en­dar in­vites, covert emails and delet­ed doc­u­ments: Pfiz­er sues ex-em­ploy­ees for al­leged­ly steal­ing trade se­crets

When Re­gor Ther­a­peu­tics un­veiled a col­lab­o­ra­tion back in De­cem­ber with Eli Lil­ly to dis­cov­er and de­vel­op new drugs for meta­bol­ic dis­or­ders, founder and CEO Xi­ayang Qiu tout­ed the deal — which gave it $50 mil­lion up­front and could be worth up to $1.5 bil­lion to­tal — as a recog­ni­tion to the “world-class re­search or­ga­ni­za­tion” and core tech­nol­o­gy his team had built in just a lit­tle over three years.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN